ZYBERNO
Stock Report
Updated Sep 1, 2026

MARKER THERAPEUTICS, INC. (MRKR)

Healthcare • NASDAQ

$1.33

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
MARKER THERAPEUTICS, INC. (MRKR) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-57.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (-271.3%)
Return on Capital (Capital Efficiency):CRITICAL (-432.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MARKER THERAPEUTICS, INC. (MRKR) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.33
Market Cap:$25.69M

Valuation Multiples (3)

P/B Ratio:2.11x
P/S Ratio:6.50x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$15.38M

Price Action & Momentum (3)

Momentum Percentile:33 / 100
% of 52-Week High:54.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-47.8%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-271.3%
Net Margin Ttm:-220.5%
Ebitda Margin:-271.3%

TTM Performance (2)

Operating Margin Ttm:-271.3%
Net Margin Ttm:-220.5%

Yield Metrics (2)

Earnings Yield:-$91.23
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:33.6%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-20.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.03x
Quick Ratio:6.03x
Cash Ratio:4.68x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:12,165,464.00
Cash And Cash Equivalents:11,331,023.00
Long Term Debt:$0.00
Net Debt:-$10.31M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $3.95M
Linear Growth: -20.7%
📊 Click to view full MRKR Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$10.71M

Bottom Line Performance (3)

-$8.71M
Income Before Tax:-$12.18M
Ebitda Ttm:-10,713,621.00

Operating Expenses (5)

Operating Expenses:13,050,002.00
R And D Expense:8,805,562.00
Sga Expense:4,244,440.00
Income Tax Expense:-$15.16K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:1,171.4%
Sga To Revenue Percentage:564.7%
Ebitda Margin:-271.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$14.59M
Current Assets:$14.59M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,420,021.00
Current Liabilities:2,420,021.00
Long Term Debt:$0.00
Short Term Debt:$1.02M

Equity & Capital (3)

Equity:$12.17M
Retained Earnings:-$464.19M
Common Stock:130,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:585,039.00

Special Items (2)

Contract Liabilities:1,352,975.00
Stock Based Compensation:195,735.00
C. Cash Flow Analysis

Operating Activities (2)

-$7.92M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,014,640.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.04
-$1.04
Earnings Per Share Ttm:-$0.45

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.20
Operating Cash Flow Per Share:-$0.62

Book Value & Capital (2)

Book Value Per Share:$0.63
Cash Per Share:0.59

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.22x
Working Capital Turnover Ttm:0.32x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:54.07
Cash Conversion Cycle:-2,052.07
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-20.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-15.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:MRKR
Company Name:MARKER THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:19.31M
Shares Outstanding Basic:19.31M
Shares Outstanding Diluted:19.31M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 10:42:12 UTC
Data Timestamp:2026-08-21T02:03:25.287510
Scroll to Top